Malaria Clinical Trial
— ORPALOfficial title:
Prevalence of Malaria Parasites in People Working in Illegal Gold Mining in French Guiana
Malaria is the most widespread parasitic illness in the world, and it is endemic to Guiana.
Although the number of cases has decreased since 2005, sources of infection still remain,
particularly within illegal gold mines. These malaria carriers/sufferers often use
self-medication to deal with malaria symptoms, resulting in a risk of resistance to
anti-malarial treatments, and particularly to artemisinine. The mobility of this population
across the Guiana Shield increases both the risk of malaria spreading and the resistance of
this illness to treatment in the region, and puts the population at risk of new outbreaks of
this disease despite the great efforts put into anti-malarial policy in this region.
Fighting malaria within this population is therefore a dual public health challenge: on the
one hand, make it possible for the WHO to eliminate malaria from the Guiana Shield by 2017,
on the other to limit resistance to artemisinine in this region. However, Guiana's
particular context - namely the illegal status of gold mines and the difficult geographical
access, the Harpie military operations, the illegality of carrying out malarial diagnosis
tests and treating cases without the presence of a health professional - prevents us from
achieving this goal using the same tools as our neighbours in Suriname, whose " Looking for
Gold, Finding Malaria " programme was a success.
A better understanding of the malarial epidemiology in this population will enable us to
propose innovative, more adapted measures to combat malaria within these guyanese
populations. This is an transversal, multicentric observational study.
Status | Completed |
Enrollment | 421 |
Est. completion date | June 2015 |
Est. primary completion date | June 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - works on a gold mining site in French Guiana - has been at the resting site for less than seven days - is over the age of 18 - accepts to take part in this study Exclusion Criteria: - refuses to take part in the study - is under the age of 18 |
Observational Model: Case-Crossover, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier de Cayenne |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | prevalence of malaria positive individuals (symptomatic or not symptomatic) | every participant gives a capillary blood specimen which is then screened for malaria using PCR in order to obtain a prevalence of malaria positive individuals (symptomatic or not symptomatic) | 1 month | Yes |
Secondary | Microscopy: thick and thin smear | Each participant is screen for malaria using classic microscopy on thin and thick smears in order to obtain a prevalence of malaria positive individuals and to evaluate parasite quantities, and gametocyte carriage (transmission potential). If either thin or thick smears are positive then the patient is estimated to have smear positive malaria. | 1 month | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |